Search Within

Jose T Baselga

Formats
  1. Meeting Abstract (241)
  2. Journal Article (233)
  3. Conference Paper (4)
  4. Research Letter (3)
  5. Book Section (2)
  6. Review (1)
Groups
  1. Department of Medicine (197)
  2. Solid Tumor Oncology Division (192)
  3. Breast Medicine Service (149)
  4. GSK Faculty (128)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (108)
  6. Human Oncology and Pathogenesis Program (97)

More Groups

People
  1. David Hyman (68)
  2. Maurizio Scaltriti (63)
  3. Clifford Hudis (57)
  4. Michael Berger (56)
  5. Larry Norton (51)
  6. Sarat Chandarlapaty (48)

More People

Years
  1. 2021 (5)
  2. 2020 (11)
  3. 2019 (25)
  4. 2018 (58)
  5. 2017 (68)
  6. 2016 (67)

More Years

Publications
  1. Cancer Research (109)
  2. Journal of Clinical Oncology (92)
  3. Annals of Oncology (29)
  4. Clinical Cancer Research (29)
  5. European Journal of Cancer (25)
  6. Cancer Discovery (13)

More Publications

Publishers
  1. American Association for Cancer Research (163)
  2. American Society of Clinical Oncology (97)
  3. Oxford University Press (41)
  4. Elsevier Inc. (39)
  5. Nature Publishing Group (30)
  6. Springer (16)

More Publishers

Results (484)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial
    Journal Article

    Goldhirsch, A.; Gelber, R. D.; Piccart-Gebhart, M. J.; de Azambuja, E.; Procter, M.; Suter, T. M.; Jackisch, C.; Cameron, D.; Weber, H. A.; Heinzmann, D.; more...
    Lancet (2013)

    Fulltext@MSK | Save
  • MTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer
    Journal Article

    Elkabets, M.; Vora, S.; Juric, D.; Morse, N.; Mino-Kenudson, M.; Muranen, T.; Tao, J.; Bosch Campos, A.; Rodon, J.; Ibrahim, Y. H.; more...
    Science Translational Medicine (2013)

    Fulltext@MSK | Save
  • Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer
    Journal Article

    Baselga, J.; Gomez, P.; Greil, R.; Braga, S.; Climent, M. A.; Wardley, A. M.; Kaufman, B.; Stemmer, S. M.; Pêgo, A.; Chan, A.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy
    Journal Article

    Prat, A.; Baselga, J.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A phase 3 trial comparing capecitabine in combination with SorafenIb or placebo for treatment of locally advanced or metastatIc HER2-negative breast Cancer (the RESILIENCE study): Study protocol for a randomized controlled trial
    Journal Article

    Baselga, J.; Costa, F.; Gomez, H.; Hudis, C. A.; Rapoport, B.; Roche, H.; Schwartzberg, L. S.; Petrenciuc, O.; Shan, M.; Gradishar, W. J.
    Trials (2013)

    Fulltext@MSK | Save
  • Bringing precision medicine to the clinic: From genomic profiling to the power ofclinical observation
    Journal Article

    Baselga, J.
    Annals of Oncology (2013)

    Fulltext@MSK | Save
  • Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study
    Journal Article

    Campone, M.; Bachelot, T.; Gnant, M.; Deleu, I.; Rugo, H. S.; Pistilli, B.; Noguchi, S.; Shtivelband, M.; Pritchard, K. I.; Provencher, L.; more...
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
    Journal Article

    Serra, V.; Eichhorn, P. J. A.; García-García, C.; Ibrahim, Y. H.; Prudkin, L.; Sánchez, G.; Rodriguez, O.; Antón, P.; Parra, J. L.; Marlow, S.; more...
    Journal of Clinical Investigation (2013)

    Fulltext@MSK | Save
  • Bolero-2: Efficacy and safety of first-line everolimus plus exemestane in advanced breast cancer
    Meeting Abstract

    Campone, M.; Gnant, M.; Neven, P.; Pistilli, B.; Rugo, H. S.; Baselga, J.; Bauly, H.; Taran, T.; Sahmoud, T.; Hortobagyi, G.
    Breast (2013)

    Fulltext@MSK | Save
  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
    Journal Article

    Swain, S. M.; Kim, S. B.; Cortes, J.; Ro, J.; Semiglazov, V.; Campone, M.; Ciruelos, E.; Ferrero, J. M.; Schneeweiss, A.; Knott, A.; more...
    Lancet Oncology (2013)

    Fulltext@MSK | Save